MPLT — MapLight Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1770069 ·
Last close
$6.57
Market Cap
$286.78M
52W High
$40.43
52W Low
$6.06
ADV30
368,442
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -55,343,000 | -51,616,000 | 477,183,000 | 55,568,000 | 31,412,000 |
| Jun 2026 | 0 | — | -63,548,000 | -60,192,000 | 368,348,000 | 71,633,000 | 20,049,000 |
| Mar 2026 | 0 | — | -64,503,000 | -60,668,000 | 418,788,000 | 55,707,000 | 18,954,000 |
| Dec 2025 | 0 | — | -83,377,000 | -79,548,000 | 479,512,000 | 46,729,000 | 21,140,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-174,668,000
Investing CF
$-250,430,000
Financing CF
$463,264,000
CapEx
$-453,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.84
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-481,380,000
Inventory
—
Receivables
—
ST Investments
$233,092,000
EBIT TTM
$-242,926,000
Pretax Income TTM
$-229,826,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,083,000 | -161,152,000 | 479,512,000 | 21,140,000 | 458,372,000 | -138,137,000 |
| Dec 2024 | — | — | — | — | 21,721,000 | 115,195,000 | — |
| Dec 2023 | — | — | — | — | 20,127,000 | 71,282,000 | — |
| Dec 2022 | — | — | — | — | 18,519,000 | 20,870,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$368,348,000
Forward EPS
$-3.30
Max Pain — expiry 2027-02-19
max pain strike: $10.00 · spot: $6.65 · call oi: 549 · put oi: 466
Expected Move to 2027-02-19:
±$7.50
(112.78%) —
implied range
$-0.85 –
$14.15
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FULC | Fulcrum Therapeutics, Inc. | $286.43M | $3.75 | — |
| EBS | Emergent BioSolutions Inc. | $288.44M | $5.61 | — |
| VCRE | Vicore Pharma Holding AB | $285.02M | $10.12 | — |
| BNTC | Benitec Biopharma Inc. | $284.35M | $8.15 | — |
| EVMN | Evommune, Inc. | $290.28M | $7.02 | — |
News headlines (Yahoo Finance, 1h cache)
MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 12:15 · Yahoo
MapLight Therapeutics to Participate in Upcoming Investor Conference
2026-11-09 21:05 · Yahoo
Down 29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in MapLight Therapeutics, Inc. (MPLT)
2026-10-16 12:35 · Yahoo
Down 34.8% in 4 Weeks, Here's Why MapLight Therapeutics, Inc. (MPLT) Looks Ripe for a Turnaround
2026-10-14 12:35 · Yahoo
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
2026-10-06 11:00 · Yahoo
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:05 · Yahoo
MapLight Therapeutics Launching $150 Million Private Placement Financing
2026-08-13 13:47 · Yahoo
MapLight Therapeutics Announces $150 Million Private Placement Financing
2026-08-13 13:10 · Yahoo
MapLight Therapeutics stock crashes on Phase II schizophrenia data
2026-07-28 15:06 · Yahoo
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
2026-07-27 23:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.